Clinical Trial
Accepted on 02 Jan 2026
Efficacy of 42-month oral administration of glucoraphanin in preventing cognitive decline in individuals at elevated risk of dementia, including those with mild cognitive impairment: A randomized, double-blind, placebo-controlled pilot study
in Nutrition, Psychology and Brain Health